News | Oncology Related Products | March 31, 2016

The History and Future of Cancer Immunotherapy

Imaging will continue to be used for response assessment as new therapies continue to develop

cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging

March 31, 2016 — In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy development paradigm, as well as his strategic vision to optimize the implementation of next-generation immunotherapies.

Immunotherapy is currently revolutionizing cancer treatment and, according to Axel Hoos, M.D., Ph.D., has the potential to improve patient outcomes significantly in the future. Hoos leads one of the Cancer Research Institute’s (CRI) programs — the Cancer Immunotherapy Consortium (CIC) — that played an important role in enabling early immunotherapy trials to succeed.

Imaging is often used to monitor patient response to this therapy, but there is difficulty in measuring treatment response because it presents very differently than traditional chemotherapy response. The tumors sometimes increase in size for a couple of months before the treatment begins to shrink tumors over time. The tumor tissue response is also often delayed and may be mistaken as ineffective in the first couple months of monitoring.

Under the leadership of Hoos, who also serves as GlaxoSmithKline’s head of immuno-oncology, the CIC initiatives highlighted how two important factors were complicating immunotherapy trials. First, immunotherapy can produce novel responses that are not accounted for in the traditional response criteria developed for chemotherapy. Second, immunotherapy’s differential effects on clinical endpoints, such as survival, need to be addressed. In addition to the development of new immune-related response criteria (irRC), Hoos also believes that the CIC’s insights helped to transform the development program for the first checkpoint blockade immunotherapy drug, the anti-CTLA-4 antibody ipilimumab (Yervoy), which unleashes the immune system and enables a stronger anti-cancer response.

With the help of the new immunotherapy-related criteria, early trials employing ipilimumab as well as other checkpoint blockade drugs, such as the anti-PD-1 antibody pembrolizumab (Keytruda) and nivolumab (Opdivo), paved the way for immunotherapy to improve the standard of care in cancer treatment. Furthermore, these stimulated cooperative efforts in the immunotherapy community that directly influenced the regulatory guidance documents of both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Moving forward, Hoos hopes that the CIC, which has since been reconstituted as an industry advisory “think tank” focused on late-stage drug development, can build on these accomplishments. According to him, several factors will drive the efforts to usher in the next generation of immunotherapies — including technologies such as cancer vaccines, re-engineered oncolytic viruses and cell-based therapies — as well as to maximize the benefits of current immune-based drugs:

  • First, immunotherapy has already started to change the standard of care in oncology, both in significant improvements in survival as well as side effects. This will substantially change the treatment landscape and will require careful integration of immunotherapies into current treatment strategies as new information becomes available;
  • Second, there is still room to improve the criteria by which clinicians can determine successful patient responses to immunotherapy;
  • Third, not all patients respond to the same treatment the same way. To ensure each patient receives the most beneficial treatment for their particular tumors, better immune biomarkers must be developed;
  • Fourth, while individual immunotherapies have already produced clinical improvements, early trials with combination therapies suggest that benefits can be improved. Determining rational strategies for combination therapies will be a high priority moving forward; and
  • Fifth, novel immunotherapy technologies already present much promise, and by incorporating recent scientific breakthroughs into the design of treatments, their effectiveness will continue to improve patient outcomes in the future.

Immunotherapy was declared the Breakthrough of the Year by Science in 2013. To ensure that immunotherapy realizes its full potential, much more must be learned about the immune system, cancer, and their interactions within the complex and ever-changing tumor environments of individual patients.

For more information: www.nature.com/reviews

Related Content

RSNA 2017 technology review of key radiology technology updates.
Feature | RSNA 2017 | November 20, 2017 | Dave Fornell
Here is an aggregation of ITN content for all major radiology technology areas this past year.
Light and Ultrasound Waves Allow More Precise Excision of Skin Cancer Tumors

3-D MSOT rendering of a basal cell carcinoma. Image courtesy of Singapore BioImaging Consortium

News | Oncology Diagnostics | November 20, 2017
Scientists and clinicians from Singapore and Germany have successfully used multispectral optoacoustic tomography (MSOT...
HealthMyne Highlights Value of Quantitative Data in Oncology Reads at RSNA 2017
News | Clinical Decision Support | November 17, 2017
November 17, 2017 — At the 2017 Radiological Society of North America (RSNA) conference, HealthMyne will demonstrate
Sponsored Content | Videos | 3-D Printing | November 17, 2017
Dee Dee Wang, M.D., Director, Structural Heart Imaging at Henry Ford Hospital, Detroit, explains how her center uses
Keith Dreyer, DO, said artificial intelligence is one of the most important developments to watch in radiology at the opening session of RSNA 2016.

Keith Dreyer, DO,  said artificial intelligence is one of the most important developments to watch in radiology at the opening session of RSNA 2016.

Feature | Artificial Intelligence | November 17, 2017
November 16, 2017 — The American College of Radiology Data Science Institute (DSI) will provide the framework, strate
Carestream Begins Shipping MyVue Center Self-Service Kiosk in Select Countries
News | PACS Accessories | November 16, 2017
Carestream Health began shipping its MyVue Center Self-Service Kiosk that can enhance patients’ ability to access and...
Siemens Healthineers Signs Service Agreement With WhidbeyHealth Community Health System
News | Population Health | November 14, 2017
November 14, 2017 — Siemens Healthineers and WhidbeyHealth of Washington State have signed a ten-year, enterprise-wid
Biop Medical Launches Cervical Cancer Diagnosis Technology at MEDICA 2017

Biop Medical cervical cancer detection system

Technology | Women's Health | November 13, 2017
November 13, 2017 — Biop Medical announced it will present its point-of-care...
Upcoming radiology conferences, meetings and events.
News | November 13, 2017
ITN maintains a comprehensive listing of radiology specialty meetings on its website at ...
Siemens Healthineers Introduces Share360 Tailored Service Portfolio
News | Imaging | November 10, 2017
November 10, 2017 — To address the specific needs of...
Overlay Init